Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Common Equity (2016 - 2025)

Historic Common Equity for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $219.8 million.

  • Voyager Therapeutics' Common Equity fell 3344.89% to $219.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $219.8 million, marking a year-over-year decrease of 3344.89%. This contributed to the annual value of $299.8 million for FY2024, which is 2684.5% up from last year.
  • As of Q3 2025, Voyager Therapeutics' Common Equity stood at $219.8 million, which was down 3344.89% from $243.9 million recorded in Q2 2025.
  • Voyager Therapeutics' Common Equity's 5-year high stood at $340.9 million during Q1 2024, with a 5-year trough of $59.0 million in Q4 2022.
  • Its 5-year average for Common Equity is $188.2 million, with a median of $199.0 million in 2023.
  • In the last 5 years, Voyager Therapeutics' Common Equity tumbled by 4741.09% in 2021 and then skyrocketed by 30040.66% in 2023.
  • Voyager Therapeutics' Common Equity (Quarter) stood at $95.1 million in 2021, then tumbled by 37.91% to $59.0 million in 2022, then soared by 300.41% to $236.3 million in 2023, then rose by 26.84% to $299.8 million in 2024, then decreased by 26.67% to $219.8 million in 2025.
  • Its last three reported values are $219.8 million in Q3 2025, $243.9 million for Q2 2025, and $272.7 million during Q1 2025.